Vireo Growth has completed its acquisition of FLUENT Corp. in an all-share deal, issuing 6,148,780 subordinate voting shares for the whole of FLUENT’s equity. Neither company attached a dollar value to the transaction, which closed on 9 November through an Ontario court-approved plan of arrangement after FLUENT’s senior lenders converted roughly US$35.7m of debt into equity, according to the joint announcement on GlobeNewswire.
The two companies signed their arrangement agreement on 29 April and amended it on 8 June. FLUENT shareholders receive 0.002351197 of a Vireo share for each FLUENT share, a ratio adjusted to reflect Vireo’s 30-for-1 share consolidation in early June. Immediately before closing, FLUENT equitised about US$30m owed under its senior secured credit agreement, followed by a further US$5.7m under a conversion agreement struck with lenders on 1 November. The Vireo shares those lenders received are locked up for six months. FLUENT expects to delist from the Canadian Securities Exchange and the OTCQB and to give up its reporting-issuer status.
The debt conversion turns a lender into a larger shareholder. Chicago Atlantic, one of FLUENT’s senior lenders, received 3,884,062 Vireo shares without paying cash, lifting its holding from 6.2% to about 11.7% on an as-converted basis, according to the early warning disclosure in the release. Its affiliates expect to receive a further 7,617,297 Vireo shares when Vireo’s proposed acquisition of certain Ohio-based entities completes.
Florida is the prize. FLUENT brings 33 dispensaries and about 117,000 sq ft of cultivation and production space, taking Vireo’s Florida estate, which already includes its Green Dragon stores, to roughly 74 operating dispensaries and 317,000 sq ft of capacity. John Mazarakis, Vireo’s chief executive, said the deal “meaningfully strengthens our position in Florida” and pointed to efficiency gains already under way from an operating budget adopted by FLUENT’s board. Matt Mundy, FLUENT’s interim chief executive, called the closing an important milestone for shareholders.
Vireo will not keep all of FLUENT’s footprint. Etain, FLUENT’s New York subsidiary, is being sold to a third-party operator under a July agreement, although its Buffalo cultivation operations will first pass to Ace Heritage, a Vireo-affiliated entity. FLUENT’s Texas business goes to Legacy Therapeutics under a purchase agreement signed in May. Both disposals still require regulatory approval.
The enlarged Vireo now reports about 210 operating dispensaries across 10 states, according to the company description in the GlobeNewswire release. The deal is the latest step in a Florida build-out: Cann.Dev reports that a Vireo subsidiary agreed to pay $21m for the Florida cultivation campus supplying its dispensary network. Consolidation is also gathering pace in Canada, where Organigram agreed on 3 November to buy Aurora Cannabis for about C$561m, StratCann reported, a deal that still requires approval from Aurora shareholders. Investors can follow listed operators on the BoC Cannabis Stocks Tracker.
For Vireo, the immediate test is integration. It must absorb 33 additional stores and a larger block of shares held by former FLUENT lenders, while the New York and Texas disposals await regulatory sign-off and the Ohio purchase remains pending. The release did not quantify any expected cost savings from the combination. Track all cannabis M&A activity on the BoC M&A Tracker.






